SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a massive surge driven by intense market speculation regarding new commercial partnerships in the AI optical interconnect space, further fueled by a significant short squeeze. The community is actively debating the sustainability of the company's valuation against its current revenue, while many are focused on the impact of potential institutional accumulation and the scarcity of available shares for shorting.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Compass Therapeutics is currently drawing significant community attention following the release of Phase 2/3 trial data for tovecimig, which met its primary efficacy endpoint in biliary tract cancer despite failing to reach statistical significance on the overall survival secondary endpoint. Investors are actively debating the company's robust balance sheet and regulatory pathway, weighing the clinical benefit against the uncertainty surrounding the study's crossover-confounded survival results.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

DRTS is gaining significant momentum as investors anticipate major catalysts, including an upcoming oral presentation of pancreatic cancer data at Digestive Disease Week and multiple ongoing clinical trial milestones. The community is actively discussing the company's progress in targeting difficult-to-treat solid tumors, with many viewing the current valuation as an accumulation opportunity ahead of potential data readouts.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending following the release of positive pivotal trial data for its in vivo CRISPR-based hereditary angioedema treatment, which has sparked significant debate regarding its commercial potential compared to existing therapies. While the community is actively discussing the validation of the company's gene-editing platform, the stock's price action remains volatile as investors weigh the breakthrough clinical results against concerns about market competition and future reimbursement.

Greenland Energy Co. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 23, 2024 and is headquartered in New York, NY.

Greenland Energy Co.

Greenland Energy (GLND) is surging as community sentiment centers on a major drilling partnership with Halliburton for a 2026 campaign in the Jameson Land Basin, which investors view as a pivotal validation of the company's Arctic oil and mineral assets. Discussions are heavily focused on the stock's low float, extreme short interest, and the potential for a significant squeeze amid heightened global interest in energy security.

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Oruka Therapeutics Inc.

Oruka Therapeutics is trending following positive interim Phase 2a results for ORKA-001 in psoriasis, which hit its primary endpoint and showed potential for annual dosing. The community is actively debating the company's long-term valuation compared to sector peers and monitoring potential dilution as the firm moves toward larger late-stage trials.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences (SGMT) is trending as the market processes the company's strategic decision to prioritize its acne program, including the upcoming initiation of a Phase 3 trial, alongside a successful capital raise of $175 million. The community is actively debating the impact of this significant equity offering on dilution versus the potential validation of the company's long-term commercial runway and accelerated development timeline for denifanstat.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is under intense focus as investors weigh the company's Q4 financial performance against a conservative 2026 outlook and the upcoming TDAPA reimbursement transition. The community is actively debating the company's commercial execution and the potential for a rebound driven by a share buyback program and upcoming Phase 3 trial data.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

The Direxion Daily Semiconductor Bear 3X Shares (SOXS) is trending as traders grapple with a historic, parabolic rally in the semiconductor sector that has triggered intense debate over whether the market is in a bubble or a sustainable growth cycle. Community sentiment is deeply polarized, with many investors aggressively betting on an imminent mean reversion after eighteen consecutive green days for the underlying chip stocks, while others warn of the inherent risks of holding leveraged inverse instruments against such strong upward momentum.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as investors react to a significant revenue outlook miss for the upcoming quarter and broader memory supply constraints that are pressuring smartphone handset sales. Community sentiment is deeply divided, with many debating the impact of these headwinds versus the potential for long-term growth through AI-powered smartphone chips, upcoming automotive design wins, and aggressive stock buyback programs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RMAX Stock Alert: Halper Sadeh LLC is Investigating Whether RE/MAX Holdings, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of RE/MAX Holdings, Inc. (NYSE: RMAX) to The Real Brokerage Inc. for either 5.152 shares of the combined company or $13.80 in...

<ul class="summary-bullets"><li>RE/MAX shareholders can choose to receive either 5.152 shares of the new company or $13.80 in cash per share, representing a roughly 72% premium over the stock’s closing price on Friday.</li><li>The Real Brokerage’s current CEO, Tamir Poleg, will serve as chairman and CEO of the combined company, which will be named Real REMAX Group.</li><li>After closing, Real shareholders are expected to own about 59% of the business.</li></ul>Shares of RE/MAX Holdings (RMAX) jumped more than 20% in pre-market trading on Monday after The Real Brokerage (REAX) announced the acquisition of the company at an enterprise value of around $880 million.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/RMAX">RMAX shares</a> would trade at their highest levels in nearly seven months. Meanwhile, <a href="https://stocktwits.com/symbol/RMAX">REAX stock</a> was down around 3%.<h2 class="st-heading-2">Real Brokerage To Own 59% Of Combined Firm</h2>Under the agreement, RE/MAX shareholders can choose to receive either 5.152 shares of the new company or $13.80 in cash per share, representing a roughly 72% premium over the stock’s closing price on Friday.After closing, Real shareholders are expected to own about 59% of the business. The deal, slated to close in the second half of 2026, is backed by financing from Morgan Stanley and Apollo Global Management.The Real Brokerage’s current CEO, Tamir Poleg, will serve as chairman and CEO of the combined company, which will be named Real REMAX Group.<h2 class="st-heading-2">Boost For Real’s Margins</h2>The combined company would have generated about $2.3 billion in annual revenue and $157 million in adjusted earnings on a pro forma basis in 2025, the company said. The deal is also expected to boost Real’s earnings and margins in the first full year after closing.The merger also brings together Real’s AI-powered brokerage model with RE/MAX’s well-established global franchise network spanning more than 120 countries and including over 145,000 agents. Both the RE/MAX and Motto Mortgage brands will continue to operate, alongside Real’s existing brokerage platform.“Together, we will create a more innovative, more productive and more connected real estate ecosystem that we believe will generate substantial long-term value for agents, franchisees, consumers and shareholders,” Poleg said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for RMAX on Stocktwits remained in the ‘extremely bullish’ territory over the past 24 hours, amid ‘extremely high’ message volumes.One user expects RMAX shares to more than double in value from current levels.<stembedurl>https://stocktwits.com/MidusS2/message/651481268</stembedurl>Another user simply said the deal makes “so much sense.”<stembedurl>https://stocktwits.com/GTMStox/message/651481761</stembedurl>The deal reflects a broader consolidation trend across the real estate industry, as firms combine to scale operations, improve technology, and attract more agents and clients in an increasingly competitive market.In March 2025, Rocket Companies (RKT) acquired Redfin, followed by Compass (COMP) striking a deal to buy Anywhere Real Estate in September. Larger brokerages can invest more in technology and offer more in-house listings, making it easier to attract agents, buyers, and sellers.RMAX shares have gained 4.5% so far this year, while REAX stock fell around 28%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/cmpx-stock-retail-buzzing-ahead-of-cancer-drug-trial-update/cZBNZa7Re2t">This Small-Cap Biotech Is Gearing Up For A Make-Or-Break Cancer Drug Data Drop</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kraken Robotics on Tuesday announced that it has entered into an agreement to acquire Covelya Group Limited.(Image Courtesy: Getty Images)

Why Did RMAX Stock Surge 20% In Pre-Market Today?

The Real Brokerage announced the acquisition of RE/MAX Holdings at an enterprise value of around $880 million.

Equity

Real to Acquire REMAX, Creating a Leading Technology-Enabled Global Real Estate Platform

The Real Brokerage Inc. (NASDAQ: REAX) (Real), a leading technology-powered real estate brokerage, and RE/MAX Holdings, Inc. (NYSE: RMAX) (RE/MAX Holdings), the parent company of RE/MAX, LLC (REMAX...

RE/MAX (RMAX) Projected to Post Quarterly Earnings on Thursday

RE/MAX (NYSE:RMAX) will be releasing its Q1 2026 earnings after the market closes on Thursday, April 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-30-remax-holdings-inc-stock...

RE/MAX HOLDINGS, INC. TO RELEASE FIRST QUARTER 2026 RESULTS ON MAY 7, 2026

RE/MAX HOLDINGS, INC. TO RELEASE FIRST QUARTER 2026 RESULTS ON MAY 7, 2026 RE/MAX HOLDINGS, INC. TO RELEASE FIRST QUARTER 2026 RESULTS ON MAY 7, 2026 PR Newswire DENVER, April 22, 2026 DENVER, April...

REMAX MARCH 2026 NATIONAL HOUSING REPORT SHOWS SPRING SALES PICKING UP

REMAX MARCH 2026 NATIONAL HOUSING REPORT SHOWS SPRING SALES PICKING UP REMAX MARCH 2026 NATIONAL HOUSING REPORT SHOWS SPRING SALES PICKING UP PR Newswire DENVER, April 20, 2026 March Home Sales Surge...

Should Value Investors Buy REMAX (RMAX) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

REMAX Agents are Most Productive for 18 Years Straight

REMAX Agents are Most Productive for 18 Years Straight REMAX Agents are Most Productive for 18 Years Straight PR Newswire DENVER, April 15, 2026 RealTrends Verified data confirms REMAX agents close...

What Makes RE/MAX (RMAX) a New Buy Stock

RE/MAX (RMAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

RE/MAX (NYSE:RMAX) Stock Price Passes Below Two Hundred Day Moving Average   - What's Next?

RE/MAX (NYSE:RMAX) Stock Crosses Below 200-Day Moving Average - Here's Why...

RE/MAX Holdings Inc - Ordinary Shares - Class A

Proxy filing

RE/MAX Holdings, Inc. engages in the provision of real estate franchise services through its subsidiaries. It operates through the following segments: Real Estate, Mortgage and Marketing Funds. The Real Estate segment consists of the company’s owned and independent global franchising operations under the RE/MAX brand name and technology and data subscription for Gadberry and the First app. The Mortgage segment consists of the firm's mortgage brokerage franchising operations under the Motto Mortgage brand name and mortgage loan processing services and licensed software under the wemlo brand. The Marketing Funds segment is involved in marketing campaigns designed to build and maintain brand awareness and the development and operation of agent marketing technology. The company was founded by David L. Liniger and Gail A. Liniger in 1973 and is headquartered in Denver, CO.

Up 5%

Down 5%

Show me the results

Which direction is the next 5% move for the S&amp;P 500?

Stocktwits

Which direction is the next 5% move for the S&P 500?

Stocktwits Polls

Investors are closely watching the $13.80 per share acquisition offer, debating if the deal provides fair value or leaves significant upside on the table.

Some traders are wary of the price action, dismissing the surge as a potential pump-and-dump or reacting to uncertainty surrounding the acquisition terms.

RMAX
RE/MAX Holdings Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RMAX News

RMAXRE/MAX Holdings Inc - Ordinary Shares - Class A